Liver Function's impact on new myelofibrosis drug tested

NCT ID NCT07480824

First seen Mar 23, 2026 · Last updated Apr 28, 2026 · Updated 5 times

Summary

This early-stage study looks at how the drug TQ05105 behaves in people with mild or moderate liver impairment compared to healthy volunteers. About 24 participants will receive a single dose to measure drug levels and check for side effects. The goal is to understand if liver function changes how the drug is processed, which helps guide future dosing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Henan University of Science & Technology

    RECRUITING

    Luoyang, Henan, 471000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)

    NOT_YET_RECRUITING

    Jinan, Shandong, 250000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.